“Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL”

Has just been published! Dr Gavin Cull,  clinical and laboratory haematologist at Sir Charles Gairdner Hospital (SCGH)  is the Principal Investigator of the Clinical Trial at SCGH, and also a co-author of the Publication, which uses Zanubrutinib.

Dr Cull (below) provided BCRWA with a quote about this exciting study:

“This trial shows that zanubrutinib, a tablet taken twice daily, is very active in chronic lymphocytic leukaemia. The response rates were very high and the CLL came under good control in nearly all the patients. The good news for patients is that zanubrutinib was well tolerated with very few having to stop the tablets due to side-effects. While longer follow-up is needed, most patients remain on zanubrutinib with their CLL under very good control”

The publication can be found here:
http://www.bloodjournal.org/content/early/2019/07/24/blood.2019001160?sso-checked=true